Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hepcidin: a Prognostic Marker of Morbidity and Mortality in Severe Sepsis?

NCT03682003 is registered in ClinicalTrials.gov with Rennes University Hospital as lead sponsor.

NCT NCT03682003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03682003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hepcidin: a Prognostic Marker of Morbidity and Mortality in Severe Sepsis?
Lead sponsor
Rennes University Hospital
Phase
Observational
Overall status
Completed
Start date
October 1, 2014
Completion date
July 12, 2017
Enrollment
114 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

severe sepsis or septic shock